Genitourinary cancer is the term used to describe cancers that affect the organs of genitourinary system which includes the kidneys, bladder, ureters, urethra, male genitalia and prostate. Of note, potentially fatal neoplasms of the prostate, bladder and kidney are some of the world’s most commonly diagnosed cancers.
A number of genetic and environmental factors may put an individual at higher risk of developing genitourinary cancer. These risk factors may be modifiable, such as smoking, or non-modifiable such as age. Infection with specific pathogens, like human papillomavirus (HPV) may also increase risk of certain genitourinary cancers.
Symptoms vary significantly between genitourinary cancers, but early detection generally results in improved prognosis and therefore raising patient awareness of what to look out for is key to improving disease outcomes.
Treatment options available to patients with genitourinary cancers include surgery, radiation therapy, chemotherapy and targeted therapies, which are often used in combination and are selected based on a range of patient and disease specific factors.
To find out more about one of the most common types of genitourinary cancer, visit our dedicated Prostate Cancer Learning Zone where you will find information on the symptoms, diagnosis and treatment of this condition.
Featured Learning Zones
Related news and insights
Dendreon Pharmaceuticals announced publication of an analysis examining real-world survival outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with Provenge (sipuleucel-T) and commonly prescribed oral treatments.
Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase III trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma met its primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumors express PD-L1 in at least 1% of cells (programmed death-ligand 1).
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.
You may be interested in...
The Union-North America Region (NAR) is the regional arm of the International Union against Tuberculosis and Lung Disease (The Union), a global public health organization with the vision to provide health solutions to the poor.
28th Conference On Retrovirus And Opportunistic Infections 2021
CROI is the preeminent meeting in the world and attracts more than 4,000 research leaders from nearly 90 countries and nearly half of CROI attendees come from outside the United States. In recent years, more than 1000 abstracts have been selected for presentation at CROI.